ArticlePublic health challenges2026
Seroprevalence of
Article in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Congenital infections caused by Objectives: This study aimed to determine the seroprevalence of TORCH infections among children and women in Bhutan's national referral hospital. Methods: A retrospective cross-sectional review of TORCH antibody test records was conducted at the Jigme Dorji Wangchuck National Referral Hospital for tests carried out between January 2019 and December 2022. The study included all children <18 years and adult women. Serological testing used rapid immunochromatographic assays (OnSite TORCH Panel) to detect immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies, and data were analyzed descriptively with subgroup comparisons by age. Results: A total of 624 participants were included, comprising 359 children (<18 years) and 265 adult females. Among children, 202 (56.9%) were male, and 153 (43.1%) were female. Seropositivity for TORCH infections varied across age groups, with the highest IgG and IgM positivity observed in neonates and infants and a subsequent rise in the reproductive age group. Herpes simplex virus (HSV) showed the highest overall seropositivity (83.8%), followed by cytomegalovirus (CMV) (82.7%), rubella (65.7%), whereas Conclusions: TORCH seropositivity varied across age groups, with HSV and CMV being the most frequently detected infections and IgG antibodies predominating. These findings provide the first baseline TORCH seroprevalence data in Bhutan, which can serve as a reference for future maternal and child health programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.